Autopsy report · NCT03050450

Study of Lenalidomide With Vorinostat in Pediatric Patients With High Grade or Progressive CNS Tumors

“Lack of feasibility to accrue patients in allotted time.”

The sponsor’s own words in the registry.

Life of this trial

• Ran for about 2 years 4 months before it stopped.
• 8 participants enrolled.
• Results were posted on the registry 2 years 4 months after it ended.

Vital statistics

Status

Terminated

Phase

Phase 1

Sponsor

Johns Hopkins All Children's Hospital

Sponsor type

University, hospital or other

Conditions

Central Nervous System Tumors

Interventions

25 mg/m2 Lenalidomide (Revlimid®) and 180 mg/m2 Vorinostat (Zolinza®); 50 mg/m2 Lenalidomide (Revlimid®) and 180 mg/m2 Vorinostat (Zolinza®); 100 mg/m2 Lenalidomide (Revlimid®) and 180 mg/m2 Vorinostat (Zolinza®); 150 mg/m2 Lenalidomide (Revlimid®) and 180 mg/m2 Vorinostat (Zolinza®); 150 mg/m2 Lenalidomide (Revlimid®) and 230 mg/m2 Vorinostat (Zolinza®)

Participants

8

Sites

1

Countries

United States

Trials that died the same way

• Abiraterone-Rechallenge Study for CRPC Patients
  “Lack of Patient accrual” (80% match in meaning)
• Randomized Trial of Image -Guided Stereotactic Radiation Therapy (IG-SRT) in Prostate Cancer
  “Lack of patient accruals.” (77% match in meaning)
• TRAUMA HELP: Healing and Analgesia With Propranolol
  “Lack of eligible patient recruits/feasibility considerations.” (75% match in meaning)
• Tenecteplase (TNK) for Loculated Pleural Effusions in Patients With Malignancy
  “Unable to accrue patients at a reasonable rate” (75% match in meaning)
• Image Guided Intensity Modulated Reirradiation (IG-IMRT) With Cetuximab for Locoregionally Confined Recurrent Head and Neck Squamous Cell Carcinoma
  “Inadequate patient accrual” (73% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.